会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Method for quantification of neurotoxin
    • 神经毒素定量方法
    • US08949033B2
    • 2015-02-03
    • US12298908
    • 2006-04-28
    • Tetsuhiro HarakawaHirotoshi NakanoYasushi ToriiSachio OkudaRyuji KajiTakashi SakamotoMotohide TakahashiSetsuji Ishida
    • Tetsuhiro HarakawaHirotoshi NakanoYasushi ToriiSachio OkudaRyuji KajiTakashi SakamotoMotohide TakahashiSetsuji Ishida
    • G01N33/50G01N33/94
    • G01N33/5088G01N33/94
    • The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin. Specifically, based on an extent of the activity of muscular relaxation of a neurotoxin from bacteria of Clostridium, the present invention relates to a method for quantification of the efficacy (potential and/or diffusion reaction) of a neurotoxin comprising the following steps of: (a) administering a neurotoxin to the hind leg muscle of one of hind legs of a non-human mammal; (b) applying electric stimulus to said non-human mammal; (c) measuring a compound muscle action potential (CMAP) by contraction of said hind leg muscle to which the neurotoxin is administered and/or of the hind leg muscle of the other hind leg to which the neurotoxin is not administered; and (d) taking amplitude data from the compound muscle action potential (CMAP) obtained by the measurement in step (c) and analyzing an extent of a decrease in amplitude to thereby quantify the efficacy of the muscular relaxing activity by the neurotoxin. In contrast to the mouse LD50 currently used as a potential unit of a botulinum toxin which is measurable at a level of only several units, the quantification method of the efficacy of a neurotoxin of the present invention allows for measurement at a level of as low as 0.01 to 1 unit and hence is a method with a high sensitivity, reproducibility and accuracy.
    • 本发明涉及一种定量测定神经毒素的肌肉松弛活性的方法。 具体而言,本发明是基于梭菌属细菌的神经毒素的肌肉弛豫活动的程度,本发明涉及一种定量神经毒素的功效(潜在和/或扩散反应)的方法,包括以下步骤:( a)将神经毒素施用于非人哺乳动物后腿之一的后腿肌肉; (b)对所述非人哺乳动物施加电刺激; (c)通过神经毒素施用的所述后腿肌肉的收缩和/或不施用神经毒素的另一后腿的后腿肌肉测定复合肌肉动作电位(CMAP); 和(d)从步骤(c)中测定得到的复合肌肉动作电位(CMAP)获取振幅数据,分析振幅减小的程度,由此量化神经毒素对肌肉松弛活性的功效。 与目前用作肉毒杆菌毒素的潜在单位的小鼠LD50相比,其可测量的水平仅为几个单位,本发明的神经毒素的功效的定量方法允许测量水平低至 0.01〜1单位,因此是具有高灵敏度,重现性和准确性的方法。
    • 3. 发明申请
    • METHOD FOR QUANTIFICATION OF NEUROTOXIN
    • 神经毒素定量方法
    • US20090297452A1
    • 2009-12-03
    • US12298908
    • 2006-04-28
    • Tetsuhiro HarakawaHirotoshi NakanoYasushi ToriiSachio OkudaRyuji KajiTakashi SakamotoMatohide TakahashiSetsuji Ishida
    • Tetsuhiro HarakawaHirotoshi NakanoYasushi ToriiSachio OkudaRyuji KajiTakashi SakamotoMatohide TakahashiSetsuji Ishida
    • A61K49/00A61P43/00G01N33/15G06F19/00G06F17/18
    • G01N33/5088G01N33/94
    • The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin. Specifically, based on an extent of the activity of muscular relaxation of a neurotoxin from bacteria of Clostridium, the present invention relates to a method for quantification of the efficacy (potential and/or diffusion reaction) of a neurotoxin comprising the following steps of: (a) administering a neurotoxin to the hind leg muscle of one of hind legs of a non-human mammal; (b) applying electric stimulus to said non-human mammal; (c) measuring a compound muscle action potential (CMAP) by contraction of said hind leg muscle to which the neurotoxin is administered and/or of the hind leg muscle of the other hind leg to which the neurotoxin is not administered; and (d) taking amplitude data from the compound muscle action potential (CMAP) obtained by the measurement in step (c) and analyzing an extent of a decrease in amplitude to thereby quantify the efficacy of the muscular relaxing activity by the neurotoxin. In contrast to the mouse LD50 currently used as a potential unit of a botulinum toxin which is measurable at a level of only several units, the quantification method of the efficacy of a neurotoxin of the present invention allows for measurement at a level of as low as 0.01 to 1 unit and hence is a method with a high sensitivity, reproducibility and accuracy.
    • 本发明涉及一种定量测定神经毒素的肌肉松弛活性的方法。 具体而言,本发明是基于梭菌属细菌的神经毒素的肌肉弛豫活动的程度,本发明涉及一种定量神经毒素的功效(潜在和/或扩散反应)的方法,包括以下步骤:( a)将神经毒素施用于非人哺乳动物后腿之一的后腿肌肉; (b)对所述非人哺乳动物施加电刺激; (c)通过神经毒素施用的所述后腿肌肉的收缩和/或不施用神经毒素的另一后腿的后腿肌肉测定复合肌肉动作电位(CMAP); 和(d)从步骤(c)中测定得到的复合肌肉动作电位(CMAP)获取振幅数据,分析振幅减小的程度,由此量化神经毒素对肌肉松弛活性的功效。 与目前用作肉毒杆菌毒素的潜在单位的小鼠LD50相比,其可测量的水平仅为几个单位,本发明的神经毒素的功效的定量方法允许测量水平低至 0.01〜1单位,因此是具有高灵敏度,重现性和准确性的方法。
    • 9. 发明申请
    • TYPE A2 BOTULINUM TOXIN PREPARATION
    • A2型BOTULINUM毒素制剂
    • US20110033431A1
    • 2011-02-10
    • US12935769
    • 2009-03-31
    • Shinji NakahiraYasushi ToriiYoshitaka GotoMiho ShinmuraSatomi MunechikaSachio OkudaShunji Kozaki
    • Shinji NakahiraYasushi ToriiYoshitaka GotoMiho ShinmuraSatomi MunechikaSachio OkudaShunji Kozaki
    • A61K35/74A61P21/00C12N1/20C07K14/33
    • A61K38/164A61K38/4893Y02A50/469
    • A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a botulinum toxin from type A1 Clostridium botulinum (type A1 botulinum toxin), said preparation comprising as an active ingredient 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX); a medicament for treating a disease with muscle overactivity for use in a patient who has a neutralizing antibody to a type A1 botulinum toxin, said medicament comprising as an active ingredient said A2 NTX; a method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin, said method comprising administering said A2 NTX to the patient; and a method for use of A2 NTX in a patient who has said neutralizing antibody. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation comprising a type A1 botulinum toxin.
    • 一种用于患有来自A1型肉毒毒素(A1型肉毒杆菌毒素)的肉毒毒素中和抗体的患者的药物制剂,所述制剂包含来自A2型肉毒毒素(A2NTX)的150kDa A型神经毒素作为活性成分, ; 用于治疗患有肌肉过度活动的疾病的药物,所述疾病用于患有A1型肉毒杆菌毒素的中和抗体的患者,所述药物包含所述A2NXX的活性成分; 用于治疗对A1型肉毒杆菌毒素具有中和抗体的患者的方法,所述方法包括向患者施用所述A2NXX; 以及在具有所述中和抗体的患者中使用A2NTX的方法。 根据本发明,当患者用包含A1型肉毒杆菌毒素的药物制剂治疗时,可以解决由中和抗体对产生的A1型肉毒杆菌毒素引起的临床反应降低的问题。